The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
about
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismPharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With SchizophreniaAripiprazole, a Drug that Displays Partial Agonism and Functional Selectivity.PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways.Dosing Recommendations of Aripiprazole Depot with Strong Cytochrome P450 3A4 Inhibitors: A Relapse Risk.Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries.Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice.The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review
P2860
Q28084069-7087479B-0FE6-4DD6-808E-AB6F98431437Q36365500-CA76D996-C9D9-48E8-9916-0AB6C975F170Q37207816-18B8E380-77EA-41A5-B321-44B45F7D756CQ38154915-18831DF2-1E5C-40E1-A175-BC95709FD7E9Q38185057-7053C51E-FB9B-4F67-ADAE-57739A6C5308Q38366480-9884FFDF-4938-4533-9DC5-269A48DC7707Q38871120-0511BDC5-4D43-47A1-AF48-5F558ED9A736Q39244947-C402C3B7-B786-4784-954C-B054584AC6AEQ39247285-944903BE-CF04-4BEB-B491-261223E1CC3EQ39284573-A61DA15F-EDE8-4006-85E3-CBEC9FB1E9D3Q39359391-D129891B-7A56-4747-93F4-44AD5D65E22EQ47937029-C415DB2E-6541-4598-906E-799BCA2BCC95Q52915492-9F28B5DC-77F3-48C1-85F2-6B411BA2AA3FQ54119984-A22AEE6B-0AB0-4A1B-8A4F-4F4F2E290135Q58567910-FBCA5CF2-340D-461E-B3F4-8D05C0073991
P2860
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The relationship between clini ...... of paroxetine or fluvoxamine.
@en
type
label
The relationship between clini ...... of paroxetine or fluvoxamine.
@en
prefLabel
The relationship between clini ...... of paroxetine or fluvoxamine.
@en
P2093
P2860
P1476
The relationship between clini ...... of paroxetine or fluvoxamine.
@en
P2093
Junichi Azuma
Koushi Higashi
Masanori Kubo
Masaya Miyatake
Sachiko Kitahara
Sumiko Hara
Tamiki Katano
Tomoko Hasunuma
Toshiko Koue
Tsutomu Fujiwara
P2860
P2888
P356
10.1007/S00228-011-1094-4
P577
2011-07-08T00:00:00Z